Benzinga Pro data, Selecta Biosciences (NASDAQ:SELB) reported Q3 sales of $24.43 million. Earnings fell to a loss of $1.97 million, resulting in a 535.62% decrease from last quarter. In Q2, Selecta Biosciences earned $452.00 thousand and total sales reached $19.66 million.

Why Is ROCE Significant?

Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, Selecta Biosciences posted an ROCE of -0.09%.

It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but does not account for factors that could affect earnings and sales in the near future.

For Selecta Biosciences, a negative ROCE ratio of -0.09% suggests that management may not be effectively allocating their capital.Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.

Upcoming Earnings Estimate

Selecta Biosciences reported Q3 earnings per share at $-0.16/share, which did not meet analyst predictions of $-0.07/share.

This article was generated by Benzinga's automated content engine and reviewed by an editor.